Tufts Medical Center
Home About Us Contact Us

 
Molecular Cardiology Research Institute
Staff Directory
Principal Investigators









text size:   

Martin Beinborn, M.D.

  Assistant Professor
Molecular Pharmacology Research Center

Tufts Medical Center

800 Washington Street, Box 7703

Boston, MA 02111

    617-636-7740

Martin Beinborn




 Martin Beinborn is an Assistant Professor of Medicine at Tufts Medical Center and the Co-Director of the Molecular Pharmacology Research Center.  He received his M.D. degree from Duesseldorf University, and went on to obtain postgraduate training in pharmacology at Hannover Medical School, Germany, as well as in molecular gastroenterology at Brigham and Women's Hospital / Harvard Medical School in Boston. In 1993, Dr. Beinborn was board-certified in the subspecialties of Pharmacology and Toxicology, and came to Tufts Medical Center to work with Dr. Alan Kopin on the molecular pharmacology of cholecystokinin/gastrin receptors. In addition to this ongoing collaboration, Dr. Beinborn has established a research program that focuses on the receptor for glucagon-like peptide, a potential target for the treatment of diabetes and obesity.

 

Research Administrator: Dionne Marshall

Key Publications

 Meng H, Krishnaji ST, Beinborn M, Kumar K.  Influence of Selective Fluorination on the Biological Activity and Proteolytic Stability of Glucagon-like Peptide-1.    Journal of Medicinal Chemistry 2008;51(22):7303-7307.  PubMed Abstract

 

Murage EN, Schroeder JC, Beinborn M, Ahn JM.  Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1.    Bioorganic & Medicinal Chemistry 2008;16(23):10106-10112.  PubMed Abstract

 

Al-Fulaij MA, Ren Y, Beinborn M, Kopin AS.  Pharmacological Analysis of Human D1 and D2 Dopamine Receptor Missense Variants.    Journal of Molecular Neuroscience 2008;34(3):211-223.  PubMed Abstract

 

Liu G, Fortin JP, Beinborn M, Kopin AS.  Four Missense Mutations in the Ghrelin Receptor Result in Distinct Pharmacological Abnormalities.    Journal Pharmacology Experimental Therapeutics 2007;322(3):1036-1043.  PubMed Abstract

 

Al-Fulaij MA, Ren Y, Beinborn M, Kopin A.  Identification of Amino Acid Determinants of Dopamine 2 Receptor Synthetic Agonist Function.    Journal of Pharmacology and Experimental Therapeutics 2007;321(1):298-307.  PubMed Abstract

 

Beinborn M.  Class B GPCRs: A hidden agonist within?    Molecular Pharmacology 2006;70(1):1-4.  PubMed Abstract

 

Mukherjee RS, McBride EW, Beinborn M, Dunlap K, Kopin AS.  Point mutations in either subunit of the GABAB receptor confer constitutive activity to the heterodimer.    Molecular Pharmacology 2006;70(4):1406-1413.  PubMed Abstract

 

Masur K, Tibaduiza EC, Chen C, Ligon B, Beinborn M.  Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining ß-cell function.    Molecular Endocrinology 2005;19(5):1373-1382.  PubMed Abstract

 

Beinborn M, Worrall CI, McBride EM, Kopin AS.  A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.    Regulatory Peptides 2005;130(1-2):1-6.  PubMed Abstract

 

Watanabe K, Beinborn M, Nagamatsu S, Ishida H, Takahashi S.  Menetrier’s disease in a patient with helicobacter pylori infection is linked to elevated glucagons-like peptide-2 activity.    Scandinavian Journal of Gastroenterology 2005;40(4):477-481.  PubMed Abstract

 

Beinborn M, Ren Y, Bläker M, Chen C, Kopin AS.  Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms.    Molecular Pharmacology 2004;65(3):753-760.  PubMed Abstract

 

Takabayashi T, Shimizu S, Clark BD, Beinborn M, Burke JF, Gelfand JA.  Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells.    Surgery 2004;135(5):544-554.  PubMed Abstract

 

Doran AC, Wan Y-P, Kopin AS, Beinborn M.  Established theory of radiation-induced decay is not generalizable to bolton-hunter labeled peptides.    Biochemical Pharmacology 2003;65:1515-1520.  PubMed Abstract

 

Kopin AS, McBride EW, Chen C, Freidinger RM, Chen D, Zhao C-M, Beinborn M.  Identification of a series of CCK-2 receptor nonpeptide agonists: Sensitivity to stereochemistry and a receptor point mutation.    Proceedings of the National Academy of Sciences, USA 2003;100(9):5525-5530.  PubMed Abstract

 

Ren Y, Blaker M, Seshadri L, McBride EW, Beinborn M, Kopin AS.  Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity.    Journal of Molecular Neuroscience 2003;20:115-123.  PubMed Abstract

 

Hearn MG, Ren Y, McBride EW, Reveillaud I, Beinborn M, Kopin AS.  A drosophila dopamine 2-like receptor: Molecular characterization and identification of multiple alternatively spliced variants.    Proceedings of the National Academy of Sciences, USA 2002;99(22):14554-14559.  PubMed Abstract

 

Tibaduiza EC, Chen C, Beinborn M.  A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain.    Journal of Biological Chemistry 2001;276(41):37787-37793.  PubMed Abstract

 

Foran SE, Carr DB, Lipkowski AW, Maszczynska I, Marchand JE, Misicka A, Beinborn M, Kopin AS, Kream RM.  A substance P-opoid chimeric peptide as a unique nontolerance-forming analgesic.    Proceedings of the National Academy of Sciences, USA 2000;97(13):7621-7626.  PubMed Abstract

 

Kopin AS, McBride EW, Schaffer K, Beinborn M.  CCK receptor polymorphisms: An illustration of emerging themes in pharmacogenomics.    Trends in Pharmacol Sciences 2000;21(9):346-353.  PubMed Abstract

 

Bläker M, Ren Y, Seshadri L, McBride EW, Beinborn M, Kopin AS.  CCK-B/gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides.    Molecular Pharmacology 2000;58:399-406.  PubMed Abstract

 

Nagy L, Morales RE, Beinborn M, Vattay P, Szabo S.  Investigation of gastroprotective compounds at subcellular level in isolated gastric mucosal cells.    American Journal Physiol Gastrointes Liver Physiol 2000;279:G1201-G1208.  PubMed Abstract

 

Foran SE, Carr DB, Lipkowski AW, Maszczynska I, Marchand JE, Misicka A, Beinborn M, Kopin AS, Kream RM.  Inhibition of morphine tolerance development by a substance P-opiod peptide chimera.    Journal of Pharmacology and Experimental Therapeutics 2000;295(3):1142-1148.  PubMed Abstract

 

Kopin AS, Mathes WF, McBride EW, Nguyen M, Al-Haider W, Schmitz F, Bonner-Weir S, Kanarek R, Beinborn M.  The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight.    Journal of Clinical Investigation 1999;103(3):383-391.  PubMed Abstract

 

Beinborn M, Chen C, DeMeo L, McBride EW, Kopin AS.  Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.    Yale Journal of Biology and Medicine 1998;71:337-346.  PubMed Abstract

 

Rindi G, Langhans N, Rehfeld JF, Beinborn M, Kopin AS.  Abnormal gastric morphology and function in CCK-B/gastrin receptor-deficient mice.    Yale Journal of Biology and Medicine 1998;71:347-354.  PubMed Abstract

 

Bläker M, Ren Y, Gordon MC, Hsu JE, Beinborn M, Kopin AS.  Mutations within the cholecystokinin-B/gastrin receptor ligand ‘pocket’ interconvert the functions of nonpeptide agonists and antagonists.    Molecular Pharmacology 1998;54:857-863.  PubMed Abstract

 

Schaffer K, McBride EW, Beinborn M, Kopin AS.  Interspecies polymorphisms confer consitutive activity to the Mastomys cholecystokinin-B/gastrin receptor.    Journal of Biological Chemistry 1998;273(44):28779-28784.  PubMed Abstract

 

Beinborn M, Quinn SM, Kopin AS.  Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties.    Journal of Biological Chemistry 1998;273(23):14146-14151.  PubMed Abstract